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An oleaginous fraction obtained from an alcohol extract of the fruit of Pterodon pubescens Benth. 
(FHPp) was microencapsulated in polymeric systems. These systems were developed using a complex 
coacervation method and consisted of alginate/medium-molecular-weight chitosan (F1-MC), alginate/
chitosan with greater than 75% deacetylation (F2-MC), and alginate/low-molecular-weight chitosan 
(F3-MC). These developed systems have the potential to both mask the taste of the extract, and to protect 
its constituents against possible chemical degradation. The influence of the formulation parameters and 
process were determined by chemical profiling and measurement of the microencapsulation efficiency 
of the oleaginous fraction, and by assessment of microcapsule morphology. The obtained formulations 
were slightly yellow, odorless, and had a pleasant taste. The average diameters of the microcapsules 
were 0.4679 µm (F2-MC), 0.5885 µm (F3-MC), and 0.9033 µm (F1-MC). The best formulation was 
F3-MC, with FHPp microencapsulation efficiency of 61.01 ± 2.00% and an in vitro release profile of 
75.88 ± 0.45%; the content of vouacapans 3–4 was 99.49 ± 2.80%. The best model to describe the release 
kinetics for F1-MC and F3-MC was that proposed by Higuchi; however, F2-MC release displayed first-
order kinetics; the release mechanism was of the supercase II type for all formulations.
Uniterms: Pterodon pubescens Benth./pharmacognosy. Sucupira. Microcapsules/preparation. 
Vouacapans. Alginate. Chitosan. Coacervation method. Natural polymers. Natural products.
Uma fração oleaginosa obtida do extrato etanólico de frutos de Pterodon pubescens Benth (FHPp) foi 
microencapsulada em um sistema polimérico. Estes sistemas foram desenvolvidos utilizando o método 
de coacervação complexa, constituído de alginato/quitosana massa molecular média (F1-MC), alginato/
quitosana com desacetilação superior a 75% (F2-MC) e alginato/quitosana de massa molecular baixa 
(F3-MC). Estes sistemas desenvolvidos têm o potencial tanto de mascarar o sabor do extrato, quanto 
de protegê-lo de possível degradação química. A influência dos parâmetros de formulação e processo 
foram determinadas por caracterização química, determinação da eficiência de microencapsulação 
da fração oleaginosa e por avaliação morfológica da microcápsula. As formulações mostraram-se 
ligeiramente amareladas, inodoras e com sabor agradável. Os diâmetros médios das microcápsulas foram 
de 0,4679 µm (F2-MC), 0,5885 µm (F3-MC) e 0,9033 µm (F1-MC). A melhor formulação foi F3-MC, 
considerando-se que apresentou eficiência de encapsulação de 61,01 ± 2,00%, e perfil de liberação in 
vitro de 75,88 ± 0,45%; o conteúdo dos vouacapanos 3-4 foi 99,49 ± 2,80%. O melhor modelo para 
descrever a cinética de liberação foi o modelo proposto por Higuchi para F1-MC e F3-MC, entretanto, 
para F2-MC foi o modelo de primeira ordem, e o mecanismo de liberação foi do tipo super caso II para 
todas as formulações.
Unitermos: Pterodon pubescens Benth./farmacognosia. Sucupira. Microcápsulas/preparação. 
Vouacapanos. Alginato. Quitosana. Método de coacervação. Polímeros naturais. Produtos naturais.
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INTRODUCTION
“Sucupira” is the common name given to several 
species of the genera Pterodon and Bowdichia, both of 
which belong to the Leguminosae family. The oil extracted 
from the fruit of the Pterodon sp. has been shown to have 
several pharmacological properties including anticancer, 
antinociceptive, and anti-inflammatory activity, and has 
been studied mainly for its effects on arthritis (Carvalho 
et al., 1999; Coelho et al., 2005; Vieira et al., 2008; 
Hoscheid et al., 2013). The raw oil extract is difficult to 
use in pharmaceutical preparations without protection of 
its lipophilic constituents, which are easily oxidized by 
exposure to air and light.
Natural polymers have potential pharmaceutical 
applications as protectants because of their low 
toxicity, biocompatibility, biodegradability, low cost, 
and natural abundance (Mahkam, 2009). Therefore,the 
use of both alginate and chitosan has been proposed 
for drug delivery. Alginates are natural polymers 
isolated from several species of brown algae and are 
composed of 2 monomers, α-l-guluronic acid and β-d-
mannuronic acid. Chitosan, another natural polymer 
derived from chitin, is a linear molecule consisting 
of d-glucosamine residues with a variable number of 
randomly located N-acetyl glucosamine groups (Mahkam, 
2009).
Microencapsulation is a technique that enables 
solid or liquid substances to be added to polymeric 
matrices or to be coated with polymers (Nesterenko et 
al., 2013; Uddin, Hawlader, Zhu, 2001; Venkatraman 
et al., 2000). The oldest, and probably the most widely 
used, microencapsulation technique involves phase 
separation by coacervation. This consists of polymer 
deposition around the active agent by modification of 
the medium’s physico-chemical properties, such as 
temperature, ionic strength, pH, and polarity (Suave 
et al., 2006). This technique involves the reversible 
association of two polymers and has some advantages 
over other techniques, including the possibility of using 
biopolymers, the absence of an organic solvent, and 
mild temperature conditions during processing (Kruif, 
Weinbreck, Vries, 2004; Schmitt et al., 1998).
In light of this knowledge, the objective of the 
present study was to develop coacervation methods to 
prepare the oleaginous fraction obtained from an alcohol 
extract of the fruit of Pterodon pubescens Benth. (FHPp). 




Alginate with a fraction of 0.28 guluronic acid 
was obtained from Sigma-Aldrich (São Paulo, Brazil). 
CaCl2 and Tween 80 were purchased from Vetec (Duque 
de Caxias, Brazil). Chitosan with an average molecular 
weight, chitosan with ≥75% deacetylation, and low-
molecular-weight chitosan were obtained from Sigma-
Aldrich (São Paulo, Brazil).
Methods
Plant material and extraction
P. pubescens seeds were obtained from the state of 
Nossa Senhora do Livramento, Mato Grosso, Brazil. The 
taxonomic identity of the respective trees was confirmed 
by Dr. Germano Guarim Neto from the Herbarium of 
the Federal University of Mato Grosso, and a voucher 
specimen (no. 20502) was deposited at the herbarium of 
the State University of Maringá.
A crude extract of P. pubescens was obtained and 
fractionation was performed as previously reported 
(Hoscheid et al., 2012). Dried fruits of P. pubescens were 
extracted with ethanol by turbo extraction (Ultra-Turrax 
UTC115KT, IKA Works, Wilmington, NC, USA) and 
the extract was filtered. The filtrate was diluted with 
water and partitioned with hexane. The organic solvent 
was evaporated in a vacuum evaporator (Büchi® R-114, 
Flawil, Switzerland) at 40 °C until complete evaporation 
of the solvent, to obtain the oleaginous fraction (FHPp).
Chemical characterization of FHPp of the alcohol 
extract of P. pubescens by gas chromatography 
coupled with mass spectrometry
Gas  ch romatography  coup led  wi th  mass 
spectrometry (GC-MS) was performed using a system 
equipped with Thermo Electron Corporation Focus GC, 
DSQ II (Marietta, USA), with an HP-5 capillary column 
(30 m × 0.25 mm). The chromatographic conditions and 
the monitoring of mass fragments (GC-MS-SIM) were 
carried out in accordance with the methodology previously 
described by Hoscheid et al. (2012), and vouacapan 
concentration was monitored using the calibration curve 
developed and validated by the same author.
Preparation of cross-linked alginate/chitosan 
microcapsules with CaCl2
For the preparation of formulations F1-MC, F2-MC 
and F3-MC, 2.50% alginate solution (w/v) containing 
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0.25% Tween 80 (w/w) and 72.13% FHPp (w/w) was 
emulsified. This emulsion was atomized using an 
atomizer with a nozzle diameter of 0.7 mm on a 0.10% 
chitosan solution (w/w) in acetic acid 1% (v/v)/CaCl2 
2.0% (w/v) that was previously homogenized at 4000 
rpm. Atomization was performed at a flow rate of 1 mL/
min and pressure of 0.5 bar. All tests were performed 
under the same conditions by changing only the type 
of chitosan used: F1-MC was prepared using medium-
molecular-weight chitosan, F2-MC using chitosan with 
≥75% deacetylation, and F3-MC using low-molecular-
weight chitosan. The whole process was conducted 
in an ice bath maintained at a temperature of -4 °C. 
The microcapsules were washed with water, coarsely 
filtered, centrifuged at 3600 rpm, and freeze-dried. 
Blank microcapsules were prepared without FHPp, but 
using the same conditions as those used for the FHPp-
loaded microcapsules. All formulations were prepared 
in triplicate.
Morphology and particle size analysis
The microcapsule surfaces were analyzed using 
scanning electron microscopy (SEM; Shimadzu SS550 
Super Scan, Kyoto, Japan) and a metallizer IC 50 ion 
coater. Particle size analysis was performed using Image 
Pro Plus software (version 4.5.0.29 for Windows) using 
Feret’s diameter as a parameter (Barber, 1993). We 
measured at least 1000 particles and determined their size 
distribution.
Thermogravimetric analysis and differential scanning 
calorimetry
Thermogravimetric analysis (TGA) and differential 
scanning calorimetry (DSC) of the polymers, FHPp, and 
microcapsules were performed in order to evaluate the 
variations in the temperature-mass relationship of the 
materials, and to evaluate possible interactions between 
the polymers and FHPp. The analyses were carried out 
using a simultaneous analyzer (NETZSCH STA 409 PC 
Luxx ®, Witterlsbacherstr, Germany) under a nitrogen 
atmosphere, with a flow rate of 50 mL/min and heating rate 
of 10 °C/min, over a temperature range of 25 to 600 °C.
X-ray diffraction
The X-ray diffraction (XRD) analysis of the 
polymers, FHPp, and microcapsules was performed using 
an X-ray diffractometer (Shimadzu LabX XRD-6000, 
Kyoto, Japan) at Cukα1, 0.1542 nm, 40 KV, and 40 mA. 
Scans were performed between intervals of 2q; the range 
was 5° to 90°, and the speed was set at 0.5 degrees with 
2q/min.
Fourier transform infrared spectroscopy
Infrared spectroscopy analysis of the polymers, 
FHPp, and microcapsules was carried out using a Fourier 
transform infrared spectrophotometer (FTIR; BOMEN, 
MB-100C26, Quebec, Canada) at a range of 400 to 4000 
cm-1 and a resolution of 1 cm-1 with samples in KBr pellets.
Fourier transform Raman spectroscopy
Fourier transform Raman (FT-Raman) spectroscopy 
analysis of the polymers, FHPp, and microcapsules was 
conducted using an FT-Ram II (Bruker, Vertex 70V, 
Ettlingen, Germany), with the following parameters: 
power, 200–250 mW; scans, 100–1500; resolution, 4 cm-1; 
crack, 5 mm; and wavelength, 1064 nm.
Microencapsulation efficiency of the oleaginous 
fraction and content of microencapsulated 
vouacapans
Loaded microcapsules (200 mg) were extracted 
with hexane (110 mL) by leaching, over 2 min, at room 
temperature, and filtered. The solvent was removed in a 
vacuum evaporator, and the extractable core material was 
dried at 80 °C for 40 min for evaporation of the residual 
solvent. The microencapsulation efficiency (ME%) was 
calculated using the following formula:
ME%=(Experimental percentage of FHPp content in 
the microcapsules/Theoretical percentage of FHPp content 
in the microcapsules) x 100.
The extractable material was resuspended in 2 mL 
of chloroform for injection and subsequent calculation of 
the vouacapan concentration (Vouacapan%) present in the 
loaded microcapsules was determined using GC-MS-SIM 
analysis.
In vitro release profile
In vitro release profiling was carried out according 
to United States Pharmacopeia 32 (2009). Briefly, 
microcapsules (760 mg) were accurately weighed and 
placed directly on dissolution test apparatus I (Erweka, 
DT-800, Heusenstamm, Germany) with a mesh size 
between 0.36 and 0.44 mm at 100 rpm and 37 ± 0.5 °C. 
The profiles were determined in sink conditions, with 
500 mL of buffer 1.2. After 180 min, the dissolution 
medium was replaced with 500 mL of buffer 6.8. Samples 
with a volume of 5.0 mL were collected at 30, 60, 90, 
150, 180, 240, 300, 480, 720, and 1440 min, by volume 
replacement, for calculating the vouacapan concentration 
in the microencapsulated FHPp, by using GC-MS-SIM. 
All release tests were performed in triplicate.
To determine the release mechanism, the results 
were analyzed using the general equation describing 
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the release of the drug from polymeric matrix systems 
(Korsmeyer et al., 1983; Peppas, 1985).
Statistical analysis
Data are presented as means ± standard deviation 
(S.D.). Results were analyzed using STATISTICA® 10.0 
software (Statsoft, Oklahoma, USA). Analysis of variance 
(ANOVA) and the post-hoc Tukey’s test were used to 
evaluate the encapsulation efficiency. P values of <0.05 
were considered statistically significant.
RESULTS AND DISCUSSION
Chemical profile
The GC-MS-SIM chemical profile of FHPp after 
microencapsulation (Figure 1) remained unchanged when 
compared with that of FHPp, i.e., the major constituents, 
geranylgeraniol and vouacapans, remained stable. The 
transformation of raw plant materials into drugs should 
preserve the pharmacological and chemical integrity of 
constituents, ensuring their potential therapeutic value and 
maintenance of their biological effect and use (Miguel, 
Miguel, 1999).
Vouacapans are furanoditerpenes involved in the 
antirheumatic, antinociceptive, and anti-inflammatory 
activities of the oil extracted from P. pubescens fruit 
(Carvalho et al., 1999; Nunan, Carvalho, Piloveloso, 
1982; Silva et al., 2004; Spindola et al., 2009; Spindola 
et al., 2010). Earlier studies by our group have identified 
the presence of 2 vouacapans in FHPp that may be directly 
involved in their potential therapeutic activity: methyl 
6α-acetoxy-7β-hydroxyvouacapan-17β-oate (vouacapan 
3) and methyl 6α-hydroxy-7β-acetoxyvouacapan-17β-oate 
(vouacapan 4) (Hoscheid et al., 2012). However, the main 
compound extracted from FHPp was previously identified 
as 14,15-epoxygeranylgeraniol (retention time 33.38 min) 
(Hoscheid et al., 2012; Mors et al., 1967) and has been 
reported to be effective as a chemoprophylactic against 
schistosomiasis (Mors et al., 1967).
Morphological and particle size analysis
SEM photomicrography indicated that  the 
microcapsules were spherical, flat, and formed clusters 
(Figure 2(a), (b), and (c)). This agglomeration is 
characterized by the residual chitosan in the process of 
cleaning tools. Similar results were found by Mladenovska 
et al. (2007), by analyzing micrographs of alginate/
chitosan particles in 5-aminosalicylic acid. The surface of 
the microcapsules prepared in the present study appeared 
FIGURE 1 - Chemical profile of FHPp before (a) and after (b) 
the process of microencapsulation (F1-MC, F2-MC, F3-MC) 
by GC-MS-TIC, and identifying of vouacapans quantified 
by GC-MS-SIM (c). Compounds with a retention time 
between 30 and 37 min, are derived from the geranylgeraniol. 
Compounds with a retention time between 39 and 45 min, 
correspond to vouacapans. V1 and V2 = not identified; 
V3 = methyl 6α-acetoxy-7β-hydroxyvouacapan-17β-oate; 
V4 = methyl 6α-hydroxy-7β-acetoxyvouacapan-17β-oate.
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TABLE I -Microencapsulation efficiency of FHPp (ME%) and content of vouacapans microencapsulated (Vouacapan%) obtained 
by GC-MS-SIM
FHPp F1-MC F2-MC F3-MC
ME (%) - 47.07 ± 2.01 57.17± 1.63 61.01± 2.00
Vouacapan 1 Concentration (µg/mL) ± S.D. 6.92 ± 0.30 0.28 ± 0.13a 1.69± 0.57b 3.04± 0.28c
Vouacapan (%) - 4.04 ± 1.78 28.25 ± 2.32 44.38 ± 1.59
Vouacapan 2 Concentration (µg/mL) ± S.D. 18.45 ± 0.36 9.76 ± 0.33a 12.85± 1.10b 15.94± 1.20c
Vouacapan (%) - 52.90 ± 3.02 69.23 ± 1.41 86.95 ± 3.93
Vouacapans 3-4 Concentration (µg/mL) ± S.D. 29.64 ± 0.53 19.32 ± 0.72a 24.37± 1.39b 28.90± 1.75c
Vouacapan (%) - 65.37 ± 2.64 83.50 ± 1.47 99.49 ± 2.80
a, b and c- One-way ANOVA post-hoc Tukey’s test, specimens differ at p < 0.05.
FIGURE 2 - Photomicrography obtained by scanning electron microscopy of microcapsules obtained from polymeric associations: 
F1-MC (a); F2-MC (b); F3-MC (c) (2700x).
porous and wrinkled, a feature of the alginate polymer 
used (Pasparakis, Bouropoulos, 2006).
The particle size analysis revealed that F2-MC had 
a lower mean diameter than the other formulations. The 
diameters of F1-MC, F2-MC, and F3-MC were 0.9033 
± 0.48 µm, 0.4679 ± 0.21 µm, and 0.5885 ± 0.33 µm, 
respectively. Furthermore, the polydispersion index was 
determined as 0.9300 for F1-MC, 0.7234 for F2-MC, and 
0.7467 for F3-MC.
ME% of the oleaginous fraction and Vouacapan%
The results of the encapsulation yield analysis 
(Table I) showed that the best association was provided 
by F3-MC, a fact confirmed by the Vouacapans%. These 
results were similar to those obtained by Peniche et al. 
(2004), who in a study of encapsulation of alginate/
chitosan in shark liver oil showed that increasing the 
concentration of alginate improves the capsule oil 
content. However, the present work was limited by the 
capacity of the peristaltic pump of the spray-dryer that 
could not atomize concentrations higher than 3% (w/v), 
which would provide enhanced results according the 
previous study by Peniche et al. (2004). The alginate 
reacts with divalent cations such as Ca+2, Sr+2, and 
Ba+2, which replace the sodium ions in guluronic acid, 
forming a network structure (Shi et al., 2011). Thus, the 
ratio of guluronic acid should be higher to enhance the 
encapsulation process.
The content of microencapsulated vouacapans 
1 obtained for all formulations was low (<50.00%), 
indicating that the type of polymer network created by 
alginate associated with chitosan, was not sufficient 
for microencapsulation. However, it should be noted 
that the Vouacapan% of vouacapans 2 and 3-4 showed 
better results, with a high recovery. The formulation 
that showed the best Vouacapan% results was F3-MC, 
which had the highest active concentration, and 
consequently microencapsulation efficiencies over 
44.38%, 86.95%,and 99.49% for vouacapans 1, 2, and 
3–4, respectively.
Thermal analysis
By comparing blank microcapsules with FHPp-
loaded microcapsules using DSC analysis (Figure 3(a) 
and (b)), it was possible to detect displacement of the 
exothermic peak from 578 °C to 467 °C. This shift is 
caused by a decrease in thermal resistance caused by the 
interaction of the matrix with FHPp alginate/chitosan, thus 
demonstrating encapsulation.
When comparing the TGA curves of blank 
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microcapsules with those of the microcapsules loaded 
with FHPp, as illustrated in Figure 3(c) and (d), we 
observed that the microencapsulation of FHPp resulted in 
an increase in water content. The first mass loss at a low 
temperature (<200 °C) corresponds to water desorption 
(Zohuriaan, Shokrolahi, 2004), and the second mass loss 
at a higher temperature (>200 °C) is attributed to polymer 
degradation (Cozic et al., 2009).
It was also observed that the microencapsulation 
process protected FHPp from degradation, since the 
residual mass of FHPp alone was 0.11%; however, on 
F1-MC this increased to 19.60% at the same temperature 
(500 °C). Similar thermal behavior was observed for the 
other microcapsules.
The thermal profile of the isolated polymers showed 
a broad endothermic peak between 25 and 100 °C, related 
to polymer dehydration, followed by decomposition. 
According to Czubenko and Druzynska (2009), the 
increased water content appears near the endothermic 
peak and drives the material to higher temperatures with 
increasing water content.
XRD
In the XRD analysis, the chitosans showed 2 
peaks at about 10° and 20°, corresponding to hydrated 
and anhydrous crystals, respectively (Figure 4a). These 
results are in agreement with those of Li et al. (2009). 
After microencapsulation, the typical chitosan peaks 
disappeared (Figure 4b) and the loaded microcapsules 
demonstrated an amorphous nature, similar to that of 
alginate. This suggested that the introduction of alginate 
on chitosan altered the crystalline structure of chitosan, 
probably preventing the formation of hydrogen bonds 
between the amino and hydroxyl groups (Li et al., 2009).
FTIR
The absorption spectrum in the infrared region of 
alginate (Figure 5a) showed absorption bands at 1613 cm-1 
attributed to the stretch of -COO, at 1101 cm-1 because of 
the stretch of -C-O-C-, and at 3443 cm-1 because of the 
stretch of the hydroxyl group linked by hydrogen bonds. 
FIGURE 3 - Thermal analysis of blank microcapsules and FHPp-loaded microcapsules. DSC blank microcapsules (a), DSC FHPp-
loaded microcapsules (b), TGA blank microcapsules (c) and TGA FHPp-loaded microcapsules (d).
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FIGURE 4 - X-ray diffraction of polymers (a), and from FHPp-loaded microcapsules (b).
Similar results have been observed by other authors (Lawrie 
et al., 2007; Pasparakis, Bouropoulos, 2006). According 
to Czubenko and Druzynska (2009), the vibrations at 
2931 cm-1 are attributable to an aliphatic C-H stretch.
The absorption spectrum for low-molecular-weight 
chitosan (Figure 5b) showed absorption bands at 3425 cm-1 
because of stretching of the hydroxyl group (OH). In 
the region between 2875 and 2940 cm-1, the observed 
FIGURE 5 - FT-IR of alginate (a), of low molecular weight chitosan (b), of FHPp (c) and of FHPp-loaded microcapsules (d).
absorption bands were associated with C-H stretching. 
The band that absorbed at 1642 cm-1 was a result of the 
predominance of the amino group (N-H). Similar results 
were found by Paulino et al. (2009) when they analyzed 
the infrared spectrum of chitosan.
In the infrared absorption spectrum of FHPp (Figure 
5c), we observed absorption bands at 1745 cm-1 attributed 
to the C=O stretch of acetates. We also saw absorption 
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at 1244 cm-1 (indicating the asymmetric C-O stretch of 
acetate), at 1017 cm-1 (indicating asymmetric stretch of 
the C-O-C ester), and at 732 cm-1 (reflecting furan rings). 
This trait was also found by Spindola et al. (2009) when 
they analyzed 6α-acetoxy,7β-hydroxy-vouacapan.
On analys is  of  the  samples  of  the  loaded 
microcapsules (Figure 5d), we noted that the absorption 
bands at 3404 cm-1, and those between 2928 and 2861 cm-1 
for FHPp were present in varying intensities in the 
microcapsules, which suggests a variable amount of 
microencapsulated oil.
FT-Raman spectroscopy
Characterization of different types of alginate 
reveals the presence of different proportions of guluronic 
and mannuronic acid units (Pereira et al., 2003). The 
presence of these acids can be determined from the 
characteristic features of their bands. While guluronic acid 
units originate from a band around 1025 cm-1, mannuronic 
acid originates at a band at approximately 1100 cm-1, as can 
be seen in Figure 6(a). Thus, the proportion of guluronic/
mannuronic acid concentration can be determined by their 
relative intensity. These bands were also used by Pereira 
et al. (2003) to characterize alginate. In the spectrum of 
low-molecular-weight chitosan (Figure 6b), we observed 
bands in the range of 2800-3000 cm-1, which is usually 
derived from stretching vibrations of CH groups (Socrates, 
2001). Therefore, a band at 2881 cm-1 can be attributed 
to these vibrations. Bands at 1419, 1116, and 1094 cm-1 
are associated with the vibrations of polysaccharide 
backbones, and bands at 1116 cm-1 and 1094 cm-1 may 
be considered indicative of the symmetric vibration of 
glycosidic bonds (Zhang et al., 2011). Analyzing the 
spectra for the FHPp-loaded microcapsules (Figure 6c) 
and comparing these with the FHPp spectra (Figure 6d), 
we found that a peak at 1673 cm-1 is characteristic of FHPp, 
and is present in all microcapsule samples, indicating 
that oil was microencapsulated. In general, for esters and 
monoesters of unsaturated dicarboxylic acids, the C=O 
bandwidth occurs approximately within the same range 
(1735-1760 cm-1). With β-keto esters, tautomerism is 
FIGURE 6 - FT-Raman of alginate (a), low molecular weight chitosan (b), of the FHPp (c) and FHPp-loaded microcapsules (d).
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possible (Socrates, 2001). In the case of tautomers, a strong 
band is observed at 1650 cm-1. The peak at 1673 cm-1 is 
reflective of the ester group (i.e., the vouacapans present 
in FHPp), where the effect of hydrogen bonding occurs. 
When an intramolecular hydrogen bond (internal) is 
present, the C=O bond shifts to a lower frequency. The 
two most striking features in the spectrum of a normal 
ester are the strong C=O band, which appears between 
1735 and 1750 cm-1, and stretch C-O bond bands, which 
appear between 1300 and 1000 cm-1 (Pavia et al., 2010).
In vitro release profile
The release profile of the FHPp-loaded microcapsules 
was generated by measuring vouacapans in FHPp. There 
was no statistically significant change between the average 
percentage of vouacapans released in F2-MC and F3-MC 
after 24 h (Figure 7); however, it was observed that the 
release of F3-MC appears to be more accelerated, which 
could be valuable for oral formulations. We observed 
that after 3 h (pH 1.2), vouacapan release from F3-MC 
was 53.85 ± 0.44%, suggesting that the FHPp may be 
primarily located at the alginate/chitosan interface, a fact 
made possible by the chitosan-induced relaxation of the 
polymer mesh.
After 24 h (pH 6.8), the release of vouacapans from 
F3-MC was 75.88 ± 0.45%, slightly lower than that from 
F2-MC (78.41 ± 2.23%); in contrast, vouacapan release 
from F1-MC was 47.64 ± 2.50%, which was significantly 
lower than the results obtained with the other two 
formulations.
According to Ribeiro et al. (2005), there is a lack of 
knowledge about the behavior of alginate microspheres 
in simulated gastric and intestinal fluids; however, it is 
known that the stability of the alginate/chitosan complex 
can be influenced by environmental parameters such as 
pH and ionic strength. Two hours under simulated gastric 
conditions can lead to the dissociation of the alginate 
matrix (Shu, Zhu, Song, 2001), providing evidence that 
this polymers not the limiting factor for the complete 
liberation of vouacapans.
According to Mi et al. (2002), the ability of alginate/
chitosan microcapsules to swell depends on the pH value. 
The lower the pH, the greater the swelling, and at pH >6.0, 
the degree of swelling is reduced. The increased swelling 
at pH<2.0 is due to the protonation of chitosan, while the 
slight increase in swelling at pH>5.0 is attributable to the 
ionization of the carboxylic group of alginate within the 
alginate/chitosan complex. This is important because the 
degree of swelling influences the process of diffusion, with 
increased swelling being associated with a higher diffusion 
rate. Microcapsules produced with low-molecular-weight 
chitosan showed less swelling compared to that shown by 
the microcapsules prepared using larger-molecular-weight 
chitosans when applied in delivery systems, and were 
associated with decreased diffusion (Liu et al., 2004).
Several authors have reported a similar percentage 
release of various drugs from alginate/chitosan beads, 
demonstrating that these polymer coatings decrease 
drug release from microcapsules (Anal, Stevens, 2005; 
González-Rodríguez et al., 2002; Rajendran, Basu, 2009; 
Yu et al., 2008).
We next examined release kinetics to determine 
which model provided the best fit for the data. We tested 
first-order Q (Mt / M ∞ = Qt = ln ‘. t) and second-order 
(Mt / M ∞ = Qt = (1 / Q). t) models, as well as the model 
proposed by Higuchi (Mt / M ∞ = Q0 + KH t1 / 2), for all 
formulations.
Following Fick’s law, Mt/M∞ = k.tn and log Mt/M∞ 
= log k + n log t constant values were obtained: a value of 
n = 0.45 indicates Case I (Fickian) diffusion or square root 
of time kinetics, 0.45 >n < 0.89 indicates anomalous (non-
Fickian) diffusion, n = 0.89 indicates Case II transport, and 
n > 0.89 indicates super case II transport (Ritger, Peppas, 
1987).
For F1-MC, it was found that the best fit was provided 
by Higuchi’s model (R = 0.9382 ± 0.0136), by Fick’s law 
of diffusion, n = 1.5347 (n > 1), r = 0.9664 ± 0.0118, and 
k = 1.37. However, for F2-MC, the best kinetics model 
was first order (R = 0.9713 ± 0.0290), by Fick’s law of 
diffusion n = 1.3733 (n > 1), r = 0.9878 ± 0.0118, and k 
= 1.14. It was found that the best fit was also provided by 
Higuchi’s model with R = 0.8782 ± 0.0136 for F3-MC, 
with diffusional n = 1.6084, i.e., n>1, r = 0.9525 ± 0.0118, 
and k = 1.55.
FIGURE 7 - In vitro  release profile of FHPp-loaded 
microcapsules.
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The n value (n>1) indicates that the release 
mechanism is of the super case II type, in which the 
simultaneous contribution of processes such as diffusion, 
swelling, relaxation, and erosion of the polymeric matrix 
does not obey a Fickian diffusion model (Korsmeyer et 
al., 1983; Peppas, 1985; Ritger, Peppas, 1987). In the 
non-Fickian diffusion process, the polymeric chains do 
not have enough mobility to allow fast penetration of the 
solvent into the polymer matrix.
CONCLUSIONS
The data revealed that the chemical profile of 
FHPp was not altered by the microencapsulation process. 
Thermal and spectroscopic analysis in the infrared region 
revealed that FHPp was microencapsulated and that the 
process protected the obtained fraction from degradation.
The crystalline chitosan structure was changed with 
the introduction of alginate, yielding amorphous 
microcapsules.
Although microcapsules developed with alginate/
chitosan with a deacetylation rate ≥75% (F2-MC) showed 
a lower mean diameter, the ME% of the oleaginous 
fraction and content of microencapsulated vouacapans 
were greater than when using the combination of alginate/
low-molecular-weight chitosan (F3-MC). The best model 
to describe the release kinetics was that proposed by 
Higuchi for F1-MC and F3-MC; however, for F2-MC, the 
first-order model was used, and the release mechanism was 
of the supercase II type for all formulations.
The most promising pre-formulation (F3-MC) 
needs further examination in order to produce a final 
formulation, and its ex vivo and in vivo stability should 
also be determined.
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